Chonnam Med J.
2021 Jan;57(1):36-43. 10.4068/cmj.2021.57.1.36.
Recent Updates of Lipoprotein(a) and Cardiovascular Disease
- Affiliations
-
- 1Division of Cardiology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea
- KMID: 2510783
- DOI: http://doi.org/10.4068/cmj.2021.57.1.36
Abstract
- In recent years, epidemiological studies, genome-wide association studies, and Mendelian randomization studies have shown a strong association between increased levels of lipoproteins and increased risks of coronary heart disease and cardiovascular disease (CVD). Although lipoprotein(a) [Lp(a)] was an independent risk factor for ASCVD, the latest international clinical guidelines do not recommend direct reduction of plasma Lp(a) concentrations. The main reason was that there is no effective clinical medicine that directly lowers plasma Lp(a) concentrations. However, recent clinical trials have shown that proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9) and second-generation antisense oligonucleotides can effectively reduce plasma Lp(a) levels. This review will present the structure, pathogenicity, prognostic evidences, and recent advances in therapeutic drugs for Lp(a).
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Recent Guideline for the Management of Dyslipidemia in Patients with Diabetes
- Recent dyslipidemia guidelines for patients with diabetes mellitus
- New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
- Lipoprotein(a): a not-so-well-known risk factor for the development of cardiovascular disease in patients with type 2 diabetes mellitus
- New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
